Loading
CD33 is a myeloid surface marker on the blasts of 85 to 90% of acute myeloid leukaemias and on normal myeloid cells, so drugs against it also hit healthy marrow. It is the target of gemtuzumab ozogamicin, the first ADC ever approved (2000), withdrawn in 2010 and re-approved in 2017 at a lower fractionated dose. This dossier gathers the 1 product (1 approved), 3 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Siglec-3; expressed on AML blasts and normal myeloid cells.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute myeloid leukaemia | 85-90% | Blast surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| ADC 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
COG AAML0531 NCT00372593 | 3 | Positive | Newly diagnosed AML, age 0-29: standard five-course chemotherapy with or without two doses of gemtuzumab ozogamicin | 3-year EFS 53.1% vs 46.9%, HR 0.83; relapse risk reduced. | |
ALFA-0701 NCT00927498 | 3 | Positive | Newly diagnosed de novo AML, age 50-70: fractionated gemtuzumab ozogamicin added to 7+3 vs 7+3 alone | EFS 17.3 vs 9.5 months; HR 0.56. | |
| 3 | Recruiting | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD33" OR ABSTRACT:"CD33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD33, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd33.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd33.json. Licence CC BY-NC 4.0.